What is LOPJLB’s current signal on SLRX?

LOPJLB’s latest quantitative signal on Salarius Pharmaceuticals, Inc. (SLRX) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is SLRX in?

Salarius Pharmaceuticals, Inc. (SLRX) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Salarius Pharmaceuticals, Inc. (SLRX) do?

Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors. Another promising program inv…

Salarius Pharmaceuticals, Inc. (SLRX)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$0.82+6.49%Close

SELLRECOVERY · day 3

RANGE

DATA 2026-01-09

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Market cap: $5M
Beta: 0.32

P/E (TTM): -0.03

1W: +26.15%
1M: -1.20%

vs SPY 1W: +24.99%
vs SPY 1M: -4.20%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

FAQ

What is LOPJLB’s current signal on SLRX?: LOPJLB’s latest quantitative signal on Salarius Pharmaceuticals, Inc. (SLRX) is SELL in a RECOVERY regime. Signals are updated daily.
What market regime is SLRX in?: Salarius Pharmaceuticals, Inc. (SLRX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Salarius Pharmaceuticals, Inc. (SLRX) do?: Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors. Another promising program inv…

Key stats

Prediction markets

Company news

FAQ